So Much Writing,So Little Science: A Review of 37 Years of Literature on Edetate Sodium Chelation Therapy

Abstract

Spanish

French

OBJECTIVE:

To determine the safety and efficacy of edetate sodium (ethylenediamine tetraacetic acid; EDTA) chelation therapy for atherosclerosis.

METHODS:

Literature search using MEDLINE, encompassing 1966 through May 1993. Further references were obtained from articles and books, and from citations obtained from the American Academy of Medical Preventics.

RESULTS:

16 case reports or case series, 2 longitudinal studies, and 3 clinical trials were reviewed, along with testimonials cited in 19 books.

CONCLUSIONS:

Little valid scientific evidence is available. Although the postulated mechanisms of action for EDTA are biologically plausible and EDTA appears to be safe, it has not been proven effective. Indeed, the best evidence shows it to be ineffective. Therefore, EDTA chelation therapy should not be used in clinical practice to treat atherosclerosis.

Get full access to this article

View all access options for this article.

References

Clarke

Mosher

. The “in vivo” dissolution of metastatic calcium: an approach to atherosclerosis. Am J Med Sci 1955; 229: 142–9.

Rathmann

Golightly

. Chelation therapy of atherosclerosis. Drug Intell Clin Pharm 1984; 18: 1000–3.

Halstead

. The scientific basis of EDTA chelation therapy. Colton, CA: Golden Quill Publishers, 1979.

Walker

. Chelation therapy: how to prevent or reverse hardening of the arteries. Atlanta: ′76 Press, 1987.

Whitaker

. You have alternatives to bypass surgery. Health Healing Lett 1993;Feb.

Jones

. Chelation therapy (letter). JAMA 1983; 250: 672.

Walker

. The chelation way: the complete book of chelation therapy. Garden City Park, NY: Avery Publishing, 1990.

McDonagh

Rudolph

. A collection of published papers showing the efficacy of EDTA chelation therapy. Gladstone, MD: McDonagh Medical Center, 1991.

Donsbach

. Chelation therapy: has the plug been pulled on our biggest killer? Huntington Beach, CA: International Institute of Health, 1981.

10.

Julian

. Pass or bypass? Chelation extends life. Hollywood, CA: Wellness Press, 1981.

11.

Harper

Gordon

. Reprints of medical literature on chelation therapy. Los Angeles: American Academy of Medical Preventics, 1975.

12.

Cranton

Brecher

. Bypassing bypass: the new technique of chelation therapy. New York: Stein and Day, 1990.

13.

Walker

Gordon

. The chelation answer. Atlanta: ′76 Press, 1983.

14.

Brecher

. Bye-bye bypass: the truth about chelation therapy. Troup, TX: Health Savers Press, 1989.

15.

Chaitlow

. Chelation therapy: the revolutionary alternative to heart surgery. San Francisco: Thorsons SF, 1991.

16.

McDonagh

. Chelation can cure: how to reverse heart disease, diabetes, stroke, high blood pressure or surgery. Kansas City: Platinum Pen Publications, 1983.

17.

Trowbridge

Walker

. Chelation therapy: the key to unclogging your arteries, improving oxygenation, treating vision problems. 3rd ed. Marble Falls, TX: Better Health Booklet Service, 1990.

18.

Walker

. The miracle healing power of chelation therapy. Canfield, OH: Fischer Publications, 1984.

19.

Clarke

Mosher

. Treatment of angina pectoris with disodium EDTA. Am J Med Sci 1956; 232: 654–66.

20.

Meltzer

. Chelation therapy. In: Seven

Johnson

, eds. Metal-binding in medicine. Philadelphia: JB Lippincott, 1960: 132–48.

21.

Clarke

Sr Clarke

Jr Mosher

. Treatment of occlusive vascular disease with disodium EDTA. Am J Med Sci 1960; 239: 732–44.

22.

Kitchell

Meltzer

Seven

. Potential uses of chelation methods in the treatment of cardiovascular diseases. Prog Cardiovasc Dis 1961; 3: 338–19.

23.

Kitchell

Palmon

Ayton

Meltzer

. The treatment of coronary artery disease with disodium EDTA. Am J Cardiol 1963; 11: 501–6.

24.

Lamar

. Chelation treatment of occlusive arteriosclerosis in diabetic patients. Angiology 1964; 15: 379–95.

25.

Lamar

. Chelation endarterectomy for occlusive atherosclerosis. J Am Geriatr Soc 1966; 14: 272–94.

26.

The American Academy of Medical Preventics. Chelation therapy. Med Lett 1981; 23: 51.

27.

Robinson

. Chelation therapy. N Z Med J 1982; 74: 750.

28.

Riordan

Cheraskin

Dirks

Tadayan

Schultz

Brizendine

. EDTA chelation/hypertension study: clinical patterns as judged by the Cornell Medical Index Questionnaire. J Orthomolecular Med 1989; 4: 91–5.

29.

Olszewer

Carter

. EDTA chelation therapy in chronic degenerative disease. Med Hypothesis 1988; 4: 91–5.

30.

Godfrey

. EDTA chelation as a treatment of arteriosclerosis N Z Med J 1990; 93: 100.

31.

Deycher

. Antioxidant therapy in the aging process. In: Emerit

Charles

, eds. Free radicals in aging. Basel: Birkauser Verlag, 1992: 93–117.

32.

Casdorph

. EDTA chelation therapy—efficacy in arteriosclerotic heart disease. J Holistic Med 1981; 3: 101–17.

33.

Casdorph

Farr

. EDTA chelation therapy III: treatment of peripheral arterial occlusion, an alternative to amputation. J Holistic Med 1983; 5: 3–15.

34.

Olszewer

Sabbag

Carter

. A pilot double-blind study of sodium magnesium EDTA in peripheral vascular disease. J Natl Med Assoc (Brazil) 1989; 82: 173–7.

35.

McGillen

Mancini

GBJ

. Inefficacy of EDTA chelation therapy for coronary atherosclerosis. N Engl J Med 1988; 318: 1618–9.

36.

Winebaugh

Geraets

. Apparent failure of edetic acid chelation therapy for the treatment of coronary atherosclerosis. DICP Ann Pharmacother 1990; 24: 22–25.

37.

Guldager

Jelnes

Jorgensen

Nielsen

Klaerke

Mogensen

EDTA treatment of intermittent claudication—a double blind placebo-controlled study. J Intern Med 1992; 231: 261–7.

38.

Foreman

Finnegan

Lushbaugh

. Nephrotoxic hazard from uncontrolled edathamil calcium-disodium therapy. JAMA 1956; 160: 1042–6.

39.

Dudley

Ritchie

Schilling

Baker

. Pathologic changes associated with use of sodium ethylene diamine tetraacetate in treatment of hypercalcemide: report of 2 cases with autopsy findings. N Engl J Med 1955; 252: 331–7.

40.

Oliver

Mehta

MB Rai

Sarees

. Acute renal failure following administration of ethylene diaminetetraacetic acid (EDTA). Tex Med 1984; 80: 40–2.

41.

Magee

. Chelation treatment in atherosclerosis. Med J Aust 1985; 142: 514–5.

42.

McDonagh

Rudolph

Cheraskin

. The effect of EDTA chelation therapy plus supportive multivitamin-trace mineral supplementation upon renal function. A study in serum creatinine. J Holistic Med 1982; 4: 146–51.

43.

McDonagh

Rudolph

Cheraskin

. The effect of EDTA chelation therapy plus supportive multivitamin-trace mineral supplementation upon renal function: a study in blood urea nitrogen (BUN). J Holistic Med 1983; 5: 163–71.

44.

Riordon

Cheraskin

Dirks

Schultz

Brizendene

. Another look at renal function and the EDTA treatment process. J Orthomolecular Med 1987; 2: 185–7.

45.

Meltzer

Kitchell

Palmon

. The long term use, side effects, and toxicity of disodium ethylenediamene tetraacetic acid (EDTA). Am J Med Sci 1961; 242: 11–7.

46.

Cranton

. Protocol of the American College of Advancement in Medicine for the Safe and Effective Administration of EDTA Chelation Therapy. In: A textbook on EDTA chelation therapy. New York: Human Sciences Press, 1989: 269–306.

47.

Craven

Morrelli

. Chelation therapy. West J Med 1975; 122: 277–8.

48.

Berkman

Michaeli

Eldor

. EDTA dependent pseudothrombocytcpenia: a clinical study of 18 patients and a review of the literature. Am J Hematol 1991; 36: 195–201.

49.

Payne

Pierre

. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 1984; 59: 123–5.

50.

Foreman

. Pharmacology of some useful chelating agents. In: Seven

Johnson

, eds. Metal-binding in medicine. Philadelphia: JB Lippincott, 1960: 82–94.

51.

Foreman

Trujillo

. The metabolism of ¹⁴C-labelled ethylene diaminetetraacetic acid in human beings. J Lab Clin Med 1954; 43: 566–7.

52.

Klaassen

. Heavy metal antagonists. In: Gilman

Rall

Nies

Taylor

, eds. Goodman and Gilman's the phamacologic basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 1607–8.

53.

Steinberg

Parthasarathy

Carew

Khoo

Witztum

. Beyond cholesterol: modification of low-density lipoprotein that increases its atherogenicity. N Engl J Med 1989; 320: 915–24.

54.

Chisolm

. Antioxidants and atherosclerosis. Clin Cardiol 1991; 14: I-25–30.

55.

Schwartz

Valente

Sprague

Kelley

Nerem

. The pathogenesis of atherosclerosis: an overview. Clin Cardiol 1991; 14: I-1–16.

56.

Ross

. The pathogenesis of atherosclerosis—an update. N Engl J Med 1986; 314: 488–500.

57.

Henry

. Atherosclerosis, calcium, and calcium antagonists. Circulation 1985; 72: 456–9.

58.

Parthasarathy

Steinberg

. Cell-induced oxidation of LDL. Curr Opinion Lipidol 1992; 3: 313–7.

59.

Salonen

Nyyssonen

Korpela

Tuomilehto

Seppanen

Salonen

. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86: 803–37.

60.

Gordon

Vance

. EDTA chelation therapy for atherosclerosis: history and mechanisms of action. Osteopathic Ann 1976; 4: 38–48.

61.

Wilder

DeJode

Milstein

Howard

. Mobilization of atherosclerotic plaque calcium with EDTA utilizing the isolation-perfusion principle. Surgery 1962; 52: 793–5.

62.

Koen

McCann

Boyle

. Some in vivo effects of chelation II: animal experimentation. J Chronic Dis 1963; 16: 329–33.

63.

Rubin

. Biologic action of chelating agents. In: Fifth Conference on Metabolic Interrelations. New York: Macy Foundation, 1954: 344–58.

64.

Demesy

. On the mechanism of papaverine action on the control of vascular smooth muscle contractile activity by extracellular calcium. J Pharm Pharmacol 1971; 23: 712–3.

65.

Kinsman

Howard

Stane

Mullins

. Studies in copper status and atherosclerosis. Biochem Soc Trans 1990; 18: 1186–8.

66.

Salonen

Seppanen

Kantola

Suntioinen

Korpela

. Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. Br Med J 1991; 302: 756–60.

67.

Ryan

Aust

. The role of iron in oxygen-mediated toxicities. Crit Rev Toxicol 1992; 22: 119–41.

68.

Stampfer

Grodstein

Rosenberg

Willett

Hennekens

. A prospective study of plasma ferritin and risk of myocardial infarction in US physicians. Proceedings of the 33rd Annual Conference on Cardiovascular Disease Epidemiology and Prevention, March 17–20, 1993, Santa Fe, NM. Dallas: American Heart Association, 1993.

69.

Sowers

. Calcium channel blockers and atherosclerosis. Am J Kidney Dis 1990; 4: 3–9.

70.

Band

Purvis

Mercuri

. Antiatherogenic properties of calcium antagonists. J Cardiovasc Pharmacol 1991; 17 (suppl 4): 587–93.

71.

Borcherding

Meeves

Klietman

Howard

. Calcium-channel antagonists for prevention of atherosclerosis. Ann Pharmacother 1993; 27: 61–7.

72.

Loaldi

Polese

Montorsi

DeCesare

Fabbiocchi

Ravagnani

Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary artery narrowings in angina pectoris. Am J Cardiol 1989; 64: 433–9.

73.

Lichtlen

Hugenholtz

Rafflenbend

Hecker

Jost

Deckers

Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990; 335: 1109–13.

74.

Altura

Brust

Bloom

Barbow

Stempak

Altura

. Magnesium dietary intake modulates blood lipid levels and atherogenesis. Proc Natl Acad Sci USA 1990; 87: 1840–4.

75.

Yasuyoshi

Tabata

Stergiopoulos

Sata

Hattori

Orimo

. Effect of dietary magnesium on development of atherosclerosis in cholesterol-fed rabbits. Arteriosclerosis 1990; 5: 732–7.